Therapeutic efficacy of rivastigmine in Alzheimer’s disease

Abstract

A 72-year-old White male complained of memory loss, trouble recalling names and events, and a regular-duty deterioration. Hypertension, type 2 diabetes, and hyperlipidemia characterized the patient’s history. He never drank alcohol or used illicit drugs. His mother had Alzheimer’s, and his father had a stroke. The patient’s physical examination was unremarkable except for a 20- out-of-30 Mini-Mental State Examination (MMSE) score, suggesting mild cognitive impairment. Rivastigmine 1.5 mg twice a day was started, with an eight-week escalation to 6 mg twice daily. He was given rivastigmine and memantine to slow cognitive impairment. Treatment efficacy and side effects were extensively examined. This report highlights the therapeutic efficacy of rivastigmine in improving cognitive function in patients with Alzheimer’s disease. The improvement in cognitive function and absence of significant adverse effects suggest that the treatment approach was effective in managing the patient's Alzheimer's disease.